[fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification - Takegawa, Naoki; Tsurutani, Junji; Kawakami, Hisato; Yonesaka, Kimio; Kato, Ryoji; Haratani, Koji; Hayashi, Hidetoshi; Takeda, Masayuki; Nonagase, Yoshikane; Maenishi, Osamu; Nakagawa, Kazuhiko (International journal of cancer, 2019)
Keywords: Animals; Antibodies, Monoclonal, Humanized - pharmacology; antibody–drug conjugate; Antineoplastic Agents - pharmacology; Antitumor activity; Camptothecin - analogs & derivatives; Camptothecin - pharmacology; Cancer; Cell Line, Tumor; Clinical trials; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - genetics; DNA topoisomerase; Epidermal growth factor; ErbB-2 protein; Female; HCT116 Cells; HER2; HT29 Cells; Humans; Immunoconjugates - pharmacology; Immunotherapy; Medical research; Mice; Mice, Inbred BALB C; Mice, Nude; Monoclonal antibodies; Proteins; Receptor, ErbB-2 - genetics; Targeted cancer therapy; Therapeutic applications; Trastuzumab; Tumor cell lines; Tumors; Xenograft Model Antitumor Assays - methods; HER2; antibody-drug conjugate; colorectal cancer